GC
CYTK icon

Guggenheim Capital’s Cytokinetics CYTK Stock Holding History

Guggenheim Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Sell
31,658
-3,481
-10% -$250K 0.02% 634
2026
Q1 		$2.32M Buy
35,139
+3,817
+12% +$243K 0.02% 655
2025
Q4 		$1.99M Buy
31,322
+440
+1% +$27.4K 0.01% 674
2025
Q3 		$1.7M Sell
30,882
-7,030
-19% -$290K 0.01% 726
2025
Q2 		$1.25M Buy
37,912
+1,209
+3% +$42.1K 0.01% 805
2025
Q1 		$1.48M Buy
36,703
+715
+2% +$32.9K 0.01% 732
2024
Q4 		$1.69M Sell
35,988
-4,898
-12% -$254K 0.01% 710
2024
Q3 		$2.16M Sell
40,886
-234
-0.6% -$13K 0.02% 802
2024
Q2 		$2.23M Sell
41,120
-548
-1% -$33.1K 0.02% 781
2024
Q1 		$2.92M Sell
41,668
-2,554
-6% -$198K 0.02% 752
2023
Q4 		$3.69M Sell
44,222
-6,780
-13% -$246K 0.03% 631
2023
Q3 		$1.5M Sell
51,002
-1,173
-2% -$39.1K 0.01% 924
2023
Q2 		$1.7M Buy
52,175
+1,219
+2% +$45.1K 0.01% 930
2023
Q1 		$1.79M Sell
50,956
-7,756
-13% -$316K 0.02% 889
2022
Q4 		$2.69M Buy
58,712
+22,670
+63% +$975K 0.02% 741
2022
Q3 		$1.75M Buy
+36,042
New +$1.73M 0.02% 888
2021
Q2 		– Sell
-9,410
Closed -$219K – 2192
2021
Q1 		$219K Sell
9,410
-9,365
-50% -$200K ﹤0.01% 2058
2020
Q4 		$390K Buy
+18,775
New +$343K ﹤0.01% 1739
2017
Q4 		– Sell
-123,456
Closed -$1.79M – 2731
2017
Q3 		$1.79M Buy
123,456
+10,201
+9% +$139K ﹤0.01% 1752
2017
Q2 		$1.37M Buy
+113,255
New +$1.57M ﹤0.01% 1882
2014
Q3 		– Sell
-17,607
Closed -$84K – 3016
2014
Q2 		$84K Sell
17,607
-290
-2% -$1.77K ﹤0.01% 3029
2014
Q1 		$170K Buy
17,897
+5,262
+42% +$47.6K ﹤0.01% 2926
2013
Q4 		$82K Buy
12,635
+1,693
+15% +$11.1K ﹤0.01% 3010
2013
Q3 		$83K Buy
+10,942
New +$117K ﹤0.01% 2874

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Guggenheim Capital's CYTK Position: Q2 2026 in Review

Guggenheim Capital reduced its Cytokinetics (CYTK) stake by 9.9% in Q2 2026, selling an estimated $250K and leaving 31,658 shares worth $2.7M. The position accounts for 0.02% of the portfolio, ranked #634.

Guggenheim Capital first reported a position in CYTK in Q3 2013 and has held it in 24 quarters since. The position peaked at $3.69M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Guggenheim Capital held 31,658 shares of Cytokinetics worth $2.7M as of Q2 2026.
  • Guggenheim Capital sold 3,481 Cytokinetics shares in Q2 2026, an estimated $250K.
  • Cytokinetics made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #634 holding.
  • Guggenheim Capital first reported a position in Cytokinetics in Q3 2013 and has held it in 24 quarters since.
  • Guggenheim Capital's Cytokinetics position peaked at $3.69M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.